TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04566939
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Study: NCT00883818
Drug: azithromycin, doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g
Study: NCT00516906
Drug: Transparent Adhesive Dressing
Normalized name: TRANSPARENT DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
Study: NCT00096135
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rescue IV over 24 hours
Study: NCT00096135
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00096135
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intramuscularly (IM)
Study: NCT00096135
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00157196
Drug: Single low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
Study: NCT02604368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule
Study: NCT01352221
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
Study: NCT00298623
Drug: XP13512 (GSK1838262)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02353702
Drug: Infusion of placebo during 48 hours
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02471118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be self-administered via subcutaneous (SC) injection
Study: NCT00004181
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02791516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injections once a month
Study: NCT01016119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
Study: NCT01037725
Drug: AZD5847
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal
Study: NCT01037725
Drug: Placebo to AZD5847
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
Study: NCT02438683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral administration
Study: NCT03763656
Drug: Oral Hydroxyurea (100 mg/mL) Solution
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
Study: NCT01165138
Drug: Placebo Inhaltion Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
Study: NCT00211757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT02645565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
Study: NCT02645565
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine will be given at 2 mg/kg.
Study: NCT02048644
Drug: fostair
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
Study: NCT02048644
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matched inhaler 2puffs to be taken twice a day for 28 days
Study: NCT05321758
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: hormones, azathioprine, thalidomide
Study: NCT02227069
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227069
Drug: M518101 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01269229
Drug: folfox
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
Study: NCT00483366
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid
Study: NCT01271010
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
Study: NCT03062280
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Modified release hydrocortisone
Study: NCT02920528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT01879462
Drug: GSK2878175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
Study: NCT01879462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually matching GSK2878175
Study: NCT00426816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match SB-649868
Study: NCT00116701
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03892668
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
Study: NCT04622891
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500
Study: NCT04622891
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin group
Study: NCT04622891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group
Study: NCT03587701
Drug: Placebo injection (Period 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
Study: NCT03587701
Drug: Placebo injection (Period 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
Study: NCT00388388
Drug: losartan, hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Study: NCT00837265
Drug: Chemotherapy Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Study: NCT00925106
Drug: Test formulation D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 150 mg celecoxib as formulation D1
Study: NCT00925106
Drug: Test formulation D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 150 mg celecoxib as formulation D3
Study: NCT01601106
Drug: liposomal prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two weekly dosages with 150 mg.
Study: NCT01601106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03286829
Drug: Tesomet High dose in fed condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study: NCT01942668
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01942668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03215758
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 once daily
Study: NCT03215758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00760435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same volume as active drug)
Study: NCT02182206
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01540630
Drug: CNV1014802
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
Study: NCT01540630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo comparator for 28 days.
Study: NCT00538967
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 weeks once daily
Study: NCT03096795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
Study: NCT02813096
Drug: folfox4 chemotherapy regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Study: NCT03257202
Drug: Clindamycin 1% Gel
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical clindamycin
Study: NCT03257202
Drug: BenzaClin 5%-1% Topical Gel
Normalized name: BenzaClin 5%-1% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin and benzoyl peroxide together
Study: NCT02642393
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules containing 500 mg of inosine
Study: NCT02642393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
Study: NCT04147390
Drug: prescribe mycophenolate mofetil(MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
Study: NCT00648427
Drug: Paxil CR™ Tablets 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, single dose fasting
Study: NCT01463696
Drug: MK-8242
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 100 mg and 150 mg capsules
Study: NCT03072394
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
Study: NCT00222235
Drug: glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00222235
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03770325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, prepared with the same appearance, for 12 weeks
Study: NCT00425698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Study: NCT02982434
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00853242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00853242
Drug: Genz-644470
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434447
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01164891
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
Study: NCT03985943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01823159
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of a tablet
Study: NCT01471379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
Study: NCT00262886
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01357538
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: corresponding vehicle, eye ointment applied to the eye lid
Study: NCT00632827
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cancer medication that interferes with the growth and spread of cancer cells in the body
Study: NCT00632827
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
Study: NCT00632827
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a chemotherapy medication used to treat cancer
Study: NCT00632827
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
Study: NCT04571424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01520701
Drug: Ialuset®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
Study: NCT00086801
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given IV
Study: NCT03597581
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Study: NCT03597581
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
Study: NCT04295681
Drug: MMH-MAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04295681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04521686
Drug: LY3410738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LY3410738
Study: NCT01262638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 12 weeks
Study: NCT03449940
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
Study: NCT01071252
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01071252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00152828
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03578575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a very low dose Danggui Buxue Tang powder.
Study: NCT04181593
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil Softgels
Study: NCT05319899
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Study: NCT02890953
Drug: Pneumostem
Approvals — FDA: no, EMA: no, PMDA: no
Description: direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
Study: NCT02890953
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: direct intracerebroventricular injection of normal saline via ventricular tap
Study: NCT01661777
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01661777
Drug: Diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00767663
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily, minimal three days pretreatment
Study: NCT00053677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects who were randomly assigned to placebo.
Study: NCT01360749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose: 2 g for 10 cm2.
Study: NCT03759886
Drug: Paromomycin Sulfate Powder
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
Study: NCT01723618
Drug: CRD007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01478126
Drug: N(2)-L-Alanine L-Glutamine dipeptide
Normalized name: N-ethyl-L-glutamine
DrugBank: Theanine (DB12444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
Study: NCT00094861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04473950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IM injection of 0.9% normal saline will be given.
Study: NCT01958645
Drug: MEDI8111
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8111 lyophilisate for solution for infusion
Study: NCT03183128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
Study: NCT03486873
Drug: Standard of Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion or oral tablets
Study: NCT03486873
Drug: MK-4280
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT02351063
Drug: Changes of heart failure medications
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
Study: NCT02547038
Drug: (panto+amox+clar+metr)+(panto+amox)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Study: NCT00964665
Drug: Pegasys®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01478126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
Study: NCT04314193
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.